natgillin/translations-raw huggingface dataset:
The field study showed that after vaccination with Versican Plus Pi/L4 the percentage of dogs with protective levels of antibodies for parainfluenza virus ranged from 73 to 97% and for leptospira 59 to 96%.
Terenska študija je pokazala, da je po cepljenju z zdravilom Versican Plus Pi/L4 zaščitne ravni protiteles proti virusu parainfluence razvilo od 73 do 97 % psov, proti leptospiri pa od 59 do 96 % psov.
This will help protect them against kennel cough and leptospirosis.
To pomaga zaščititi pse pred kužnim kašljem in leptospirozo.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega samoinjiciranja zdravila se je treba takoj posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali ovojnino.
hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation).
hepatitis (vnetje jeter) in zlatenico ali nefritis (vnetje ledvic).
The vaccine is given to puppies from six weeks of age as an injection, under the skin, and repeated three to four weeks later.
Cepivo se daje pasjim mladičem, starim šest tednov ali več, z injiciranjem pod kožo, cepljenje pa je treba ponoviti čez tri do štiri tedne.
• canine parainfluenza virus, which causes kennel cough;
• virusom pasje parainfluence, ki povzroča kužni kašelj;
The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus Pi/L4 on 31 July 2014.
Evropska komisija je dovoljenje za promet z zdravilom Versican Plus Pi/L4, veljavno po vsej Evropski uniji, izdala dne 31. julija 2014.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus Pi/L4 exceed the risks for the approved indications and recommended that Versican Plus Pi/L4 be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Versican Plus Pi/L4 večje od z njim povezanih tveganj za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
Versican Plus Pi/L4 is a veterinary vaccine that contains live attenuated (weakened) canine parainfluenza virus type 2 as well as inactivated (killed) strains of Leptospira bacteria (Icterohaemorrhagiae, Canicola, Bratislava and Grippotyphosa).
Versican Plus Pi/L4 je cepivo za uporabo v veterinarski medicini, ki vsebuje živ atenuiran (oslabljen) virus pasje parainfluence tipa 2 ter inaktivirane (uničene) seve bakterij Leptospira (icterohaemorrhagiae, canicola, bratislava ter grippotyphosa).
The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus Pi/L4 is a short lived swelling of up to 5 cm which may occur at the injection site after vaccination.
Najpogostejši neželeni učinek cepiva Versican Plus Pi/L4 (opažen pri več kot 1 psu od 100) je kratkotrajna oteklina v velikosti do 5 cm, ki se lahko po cepljenju pojavi na mestu injiciranja.
When Versican Plus Pi/L4 is given to dogs the animals' immune system recognises the viruses and bacteria as ‘foreign' and makes antibodies against them.
Ko psi prejmejo cepivo Versican Plus Pi/L4, imunski sistem živali prepozna viruse in bakterije kot „tujke“ ter začne proti njim tvoriti protitelesa.
Versican Plus Pi/L4 is used to protect dogs against:
Zdravilo Versican Plus Pi/L4 se uporablja za zaščito psov pred:
The canine parainfluenza virus in Versican Plus Pi/L4 is alive but has been attenuated (weakened) so that it does not cause disease; it is combined with killed (inactivated) strains of Leptospira bacteria.
Virus pasje parainfluence v zdravilu Versican Plus Pi/L4 je živ, vendar atenuiran (oslabljen), tako da ne povzroča bolezni; kombiniran je z uničenimi (inaktiviranimi) sevi bakterij Leptospira.
Versican Plus Pi/L4 is a vaccine.
Versican Plus Pi/L4 je cepivo.
For revaccination a single dose of Versican Plus Pi/L4 is required annually.
Za ponovno cepljenje je potreben enkraten odmerek cepiva Versican Plus Pi/L4 enkrat na leto.
Canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine
cepivo proti virusu pasje parainfluence (živo atenuirano) in proti pasji leptospirozi (inaktivirano)
Versican Plus Pi/L4 contains an adjuvant (aluminium hydroxide) to enhance the immune response.
Zdravilo Versican Plus Pi/L4 vsebuje dodatek (aluminijev hidroksid), ki spodbuja imunski odziv.
What benefit has Versican Plus Pi/L4 shown during the studies?
Kakšne koristi je zdravilo Versican Plus Pi/L4 izkazalo med študijami?
Versican Plus Pi/L4 is available as a lyophilisate (freeze-dried pellet) with solvent for injection.
Zdravilo Versican Plus Pi/L4 je na voljo v obliki liofilizata (pelete, posušene v zamrznjenem stanju) z vehiklom za injiciranje.
Other information about Versican Plus Pi/L4:
Druge informacije o zdravilu Versican Plus Pi/L4:
Why has Versican Plus Pi/L4 been approved?
Zakaj je bilo zdravilo Versican Plus Pi/L4 odobreno?
What is the risk associated with Versican Plus Pi/L4?
Kakšna tveganja so povezana z zdravilom Versican Plus Pi/L4?
How has Versican Plus Pi/L4 been studied?
Kako je bilo zdravilo Versican Plus Pi/L4 raziskano?
What is Versican Plus Pi/L4?
Kaj je zdravilo Versican Plus Pi/L4?
What is Versican Plus Pi/L4 used for?
Za kaj se zdravilo Versican Plus Pi/L4 uporablja?
How does Versican Plus Pi/L4 work?
Kako zdravilo Versican Plus Pi/L4 deluje?
The recommended dose is one 150 microgram capsule, once a day at the same time each day.
Priporočeni odmerek je ena 150-mikrogramska kapsula enkrat na dan vedno ob istem času.
It works by attaching to beta-2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax.
Deluje tako, da se veže na receptorje beta-2, ki se nahajajo v mišičnih celicah številnih organov, kar povzroči sprostitev mišic.
The full EPAR for Onbrez Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Onbrez Breezhaler je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
European Commission granted a marketing authorisation valid throughout the European Union for Onbrez Breezhaler on 30 November 2009.
Evropska komisija je dovoljenje za promet z zdravilom Onbrez Breezhaler, veljavno po vsej Evropski uniji, izdala 30. novembra 2009.
The main measure of effectiveness was based on changes in the patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks.
Glavno merilo učinkovitosti je bila sprememba forsiranega ekspiracijskega volumna (FEV1 - največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) pri bolnikih po 12-tedenskem zdravljenju.
To receive a dose, the patient places a capsule into the inhaler and breathes the powder in through the mouth.
Odmerek se vzame tako, da bolnik namesti kapsulo v inhalator in skozi usta vdihne prašek iz kapsule.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.
KOPB je dolgotrajna bolezen, pri kateri so dihalne poti in zračni mešički v pljučih poškodovani ali zamašeni, zaradi česar je dihanje oteženo.
This is a summary of the European public assessment report (EPAR) for Onbrez Breezhaler.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Onbrez Breezhaler.
This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
To povzroči sprostitev mišic dihalnih poti, kar pomaga ohranjati dihalne poti prehodne in bolniku omogoča, da lažje diha.
The increase in FEV1 was 130 ml with tiotropium, and 80 ml with formoterol.
Izboljšanje FEV1 s tiotropijem je bilo 130 ml, s formoterolom pa 80 ml.
The medicine contains the active substance indacaterol.
Zdravilo vsebuje zdravilno učinkovino indakaterol.
Overall, the effects of the 150 and 300 microgram doses of Onbrez Breezhaler were similar, but the results showed that the 300 microgram dose may provide better relief in patients with more severe disease.
V splošnem so bili učinki 150- in 300-mikrogramskih odmerkov zdravila Onbrez Breezhaler podobni, rezultati pa so pokazali, da lahko 300-mikrogramski odmerek bolnikom s hujšo obliko bolezni bolj pomaga.
Therefore, the Agency decided that Onbrez Breezhaler's benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je zaključila, da so koristi zdravila Onbrez Breezhaler večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Onbrez Breezhaler is used for maintenance (regular) treatment.
Zdravilo Onbrez Breezhaler se uporablja za vzdrževalno (redno) zdravljenje.
The most common side effects with Onbrez Breezhaler (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat) and upper respiratory tract infection (infection of the nose and throat).
Najpogostejša neželena učinka zdravila Onbrez Breezhaler (ki se lahko pojavita pri več kot 1 bolniku od 10) sta nazofaringitis (vnetje nosu in žrela) in okužba zgornjih dihal (okužba nosu in grla).
Other common side effects include chest pain, cough and muscle cramps.
Drugi pogosti neželeni učinki so bolečina v prsnem košu, kašelj in mišični krči.
What measures are being taken to ensure the safe and effective use of Onbrez Breezhaler?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Onbrez Breezhaler?
On average, the increase in FEV1 in patients who received Onbrez Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml.
FEV1 se je pri bolnikih, ki so prejemali zdravilo Onbrez Breezhaler, povprečno izboljšal od 150 do 190 ml, pri bolnikih, ki so prejemali placebo, pa je sprememba FEV1 segala od poslabšanja za 10 ml do izboljšanja za 20 ml.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onbrez Breezhaler have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Onbrez Breezhaler upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
In three main studies involving over 4,000 patients with COPD, Onbrez Breezhaler was compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
V treh glavnih študijah, v katere je bilo vključenih več kot 4 000 bolnikov s KOPB, so zdravilo Onbrez Breezhaler primerjali s placebom (zdravilom brez zdravilne učinkovine), tiotropijem in formoterolom (drugimi inhalacijskimi zdravili za zdravljenje KOPB).
Onbrez Breezhaler capsules, which contain a power for inhalation, are only used with a Onbrez Breezhaler inhaler and must not be swallowed.
Kapsule zdravila Onbrez Breezhaler, ki vsebujejo prašek za inhaliranje, je treba uporabljati izključno z inhalatorjem za zdravilo Onbrez Breezhaler in se jih ne sme pogoltniti.
For more information about treatment with Onbrez Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Onbrez Breezhaler preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Agency also noted that there were no major safety concerns with Onbrez Breezhaler, with side effects being manageable and similar to other beta-2 adrenergic receptor agonist medicines.
Ugotovila je tudi, da ni večjih pomislekov glede varnosti zdravila Onbrez Breezhaler, saj so njegovi neželeni učinki obvladljivi in podobni kot pri drugih agonistih adrenergičnih receptorjev beta-2.
The doctor may increase the dose to one 300 microgram capsule once a day in cases of severe COPD.
Pri hudi KOPB lahko zdravnik poveča odmerek na eno 300-mikrogramsko kapsulo enkrat na dan.
The active substance in Onbrez Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist.
Zdravilna učinkovina v zdravilu Onbrez Breezhaler, indakaterol, je agonist adrenergičnih receptorjev beta-2.
For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Onbrez Breezhaler naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Onbrez Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Zdravilo Onbrez Breezhaler se uporablja za ohranjanje odprtih dihalnih poti pri odraslih s kronično obstruktivno pljučno boleznijo (KOPB).
The European Medicines Agency concluded that Onbrez Breezhaler was shown to be effective at improving the lung function in COPD.
Evropska agencija za zdravila je zaključila, da je zdravilo Onbrez Breezhaler dokazano učinkovito pri izboljševanju delovanja pljuč pri KOPB.
When Onbrez Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them.
Ob vdihanju zdravila Onbrez Breezhaler indakaterol doseže receptorje v dihalnih poteh in jih aktivira.
For the full list of all side effects and restrictions with Onbrez Breezhaler, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Onbrez Breezhaler glejte navodilo za uporabo.
Other information about Onbrez Breezhaler
Druge informacije o zdravilu Onbrez Breezhaler
What is Onbrez Breezhaler and what is it used for?
Kaj je zdravilo Onbrez Breezhaler in za kaj se uporablja?
What benefits of Onbrez Breezhaler have been shown in studies?
Kakšne koristi je zdravilo Onbrez Breezhaler izkazalo v študijah?
What are the risks associated with Onbrez Breezhaler?
Kakšna tveganja so povezana z zdravilom Onbrez Breezhaler?
Onbrez Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
Zdravilo Onbrez Breezhaler je delovanje pljuč pri bolnikih s KOPB izboljšalo učinkoviteje kot placebo.
Why is Onbrez Breezhaler approved?
Zakaj je bilo zdravilo Onbrez Breezhaler odobreno?
How is Onbrez Breezhaler used?
Kako se zdravilo Onbrez Breezhaler uporablja?
How does Onbrez Breezhaler work?
Kako zdravilo Onbrez Breezhaler deluje?
20 October 2015 EMA/481797/2015
oktober 2015 EMA/481797/2015
The expressed juice may then be dried.
Iztisnjen sok je nato mogoče posušiti.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
To pomeni, da obstajajo podatki v literaturi z znanstvenimi dokazi o njihovi učinkovitosti in varnosti pri uporabi na navedeni način, ki zajemajo obdobje vsaj 10 let v EU.
This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
To pomeni, da je kljub nezadostnim dokazom iz kliničnih preskušanj učinkovitost teh zdravil rastlinskega izvora verjetna in da obstajajo dokazi, da so se na ta način varno uporabljala že vsaj 30 let (najmanj 15 let tudi v EU).
However, these data were insufficient to be used as evidence of effectiveness and the HMPC conclusions for this indication are based on the medicines' long-standing use.
Vendar so bili ti podatki nezadostni, da bi jih lahko uporabili kot dokaz učinkovitosti, zato ugotovitve odbora HMPC za to indikacijo temeljijo na dolgotrajni uporabi teh zdravil.
When used for prevention and treatment of common cold, cases of serious allergic reactions (such as Stevens-Johnson syndrome, asthma and anaphylactic shock) have been reported, especially in patients who are atopic (have a predisposition to allergic reactions).
Pri uporabi za preprečevanje in zdravljenje navadnih prehladov so poročali o primerih resnih alergijskih reakcij (kot so Stevens-Johnsonov sindrom, astma in anafilaktični šok), zlasti pri bolnikih, ki so atopični (nagnjeni k alergijskim reakcijam).
For further information on the studies assessed by the HMPC, see the HMPC assessment report.
Za podrobnejše informacije o študijah, ki jih je ocenil odbor HMPC, glejte njegovo poročilo o oceni zdravila.
The HMPC noted possible beneficial effects on wound healing in animal studies.
Odbor HMPC je upošteval možne koristne učinke pri celjenju ran iz študij na živalih.
Purple coneflower herb medicines should only be used in adults and adolescents above the age of 12 years.
Zdravila, ki vsebujejo zel škrlatne ehinaceje, se lahko uporabljajo samo pri odraslih in mladostnikih, starejših od 12 let.
The flowering aerial parts for medicinal uses are obtained from plants that have been cultivated or found in the wild.
Cvetoči nadzemni deli za medicinsko uporabo se pridobivajo iz rastlin, ki so bile gojene ali divje rastoče.
This summary is not intended to provide practical advice on how to use medicines containing purple coneflower herb.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel škrlatne ehinaceje.
Purple coneflower herb is the common name for the flowering aerial parts of the plant Echinacea purpurea (L.) Moench.
Zel škrlatne ehinaceje je splošno ime za cvetoče nadzemne dele rastline Echinacea purpurea (L.) Moench.
Further information on the risks associated with purple coneflower herb medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo zel škrlatne ehinaceje, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Herbal medicines containing purple coneflower herb preparations are usually available in liquid or solid forms to be taken by mouth and in semi-solid (such as ointments) or liquid forms to be applied to the skin.
Zdravila rastlinskega izvora, ki vsebujejo pripravke iz zeli škrlatne ehinaceje, so navadno na voljo v tekočih ali trdnih oblikah, ki se jemljejo peroralno (uživajo skozi usta), ali v poltrdnih (kot so mazila) ali tekočih oblikah, ki se nanašajo na kožo.
Purple coneflower herb medicines must not be used in patients who are hypersensitive (allergic) to purple coneflower or other plants of the Asteraceae (Compositae) family.
Zdravila, ki vsebujejo zel škrlatne ehinaceje, se ne smejo uporabljati pri bolnikih, ki so preobčutljivi (alergični) na škrlatno ehinacejo ali druge rastline iz družine nebinovk - Asteraceae (Compositae).
Any applications for the licensing of medicines containing purple coneflower herb have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo zel škrlatne ehinaceje, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
The most relevant clinical trials performed in adults indicated that purple coneflower herb medicines containing the expressed juice to be taken by mouth can prevent and improve the symptoms of cold more rapidly than placebo when taken early.
Najpomembnejša klinična preskušanja na odraslih so pokazala, da lahko zdravila, ki vsebujejo iztisnjen sok zeli škrlatne ehinaceje in se jemljejo peroralno (uživajo skozi usta), preprečijo in izboljšajo simptome prehlada hitreje kot placebo, kadar se začnejo jemati dovolj zgodaj.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing purple coneflower herb.
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo zel škrlatne ehinaceje.
Information on the use and licensing of purple coneflower leaf medicines in EU Member States should be obtained from the relevant national authorities.
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo zel škrlatne ehinaceje, v državah članicah EU se obrnite na pristojni nacionalni organ.
Further information on the HMPC assessment of purple coneflower herb medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o oceni zdravil, ki vsebujejo zel škrlatne ehinaceje, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
For the treatment of superficial wounds, a doctor or a qualified healthcare practitioner should be consulted if symptoms
Pri zdravljenju površinskih ran se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem, če simptomi trajajo dlje kot teden dni.
How are purple coneflower herb medicines approved in the EU?
Kako so zdravila, ki vsebujejo zel škrlatne ehinaceje, odobrena v EU?
The HMPC conclusions on the short-term use of purple coneflower herb medicines to prevent and treat common cold are based on their ‘well-established use' in this indication.
Zaključki odbora HMPC o kratkotrajni uporabi zdravil, ki vsebujejo zel škrlatne ehinaceje, za preprečevanje in zdravljenje navadnih prehladov temeljijo na njihovi „dobro uveljavljeni medicinski uporabi“ pri tej indikaciji.
The HMPC conclusions on the use of purple coneflower herb medicines for superficial wounds are based on their ‘traditional use'.
Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo zel škrlatne ehinaceje, za zdravljenje površinskih ran temeljijo na njihovi „tradicionalni uporabi“.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of purple coneflower herb.
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo zeli škrlatne ehinaceje.
In its assessment, the HMPC considered a number of clinical studies comparing purple coneflower herb medicines with placebo for short-term prevention and treatment of upper airways infections.
V svoji oceni je odbor HMPC upošteval več kliničnih študij, v katerih so zdravila, ki vsebujejo zel škrlatne ehinaceje, primerjali s placebom za kratkotrajno preprečevanje in zdravljenje okužb zgornjih dihal.
For more information about treatment with purple coneflower herb medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravili, ki vsebujejo zel škrlatne ehinaceje, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
Purple coneflower herb preparations are made by expressing the juice of the fresh herb.
Pripravki iz zeli škrlatne ehinaceje se pridobivajo z iztiskanjem soka iz sveže zeli.
What evidence supports the use of purple coneflower herb medicines?
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo zel škrlatne ehinaceje?
The HMPC also concluded that, on the basis of their long-standing use, purple coneflower herb medicines to be applied to the skin can be used to treat small superficial wounds.
Na podlagi njihove dolgotrajne uporabe je odbor HMPC prav tako zaključil, da se zdravila, ki vsebujejo zel škrlatne ehinaceje in se nanašajo na kožo, lahko uporabljajo za zdravljenje majhnih površinskih ran.